Garber Miguel

3 dimensional image about global regenerative academy

M.D. Garber Miguel


Miguel Garber has over 34 years experience in Internal medicine and cardiology, with expertise in regenerative medicine, training and education, research, product development and senior management. He has more than 18 years working with Stem Cell, including building and managing the stem cell evaluation, explore and developing stem cell therapies for cardiomyopathies, osteoarthritis and regenerative medicine at Stem cell Therapeutics Department of American Medical Information Group, Clinica Quirurgica Quantum and Mont Tabor investigation clinic. He is currently serving as Medical Director of Revitacell and Clinical Director of regenerative Medicine department at Clinica Castelló 68, President of Spanish Society of regenerative medicine and cell therapy on going of several investigative research involved Stem Cells application (ASC) and Drug stimulating stem cells, speaker in several congres national and international in Regenerative medicne, Professor in Master in regenerative Medicine. Dr. Garber has made a significant contribution to Stem cell Research. Actually he is involved in Adipose Stem Cell application,


Noninvasive Assessment of Stromal Vascular Fraction Graft in Myocardial Infarction: Impact on Cardiac Function and Scar Healing

Work Experience

Chief of department, Ulcinj

Since 2013
Emergency medicine centre of Montenegro


Since 2013
RENOVA clinic, Belgrade, Serbia

Medical director

Since 2011
B.L.A & Co doo, Belgrade, Serbia


Fellow, Department of Extra Corporeal Blood Management

Catharina hospital Eindhoven, The Netherlands

Medical License General medicine


Fellowship, Clinical genetics and intercellular signaling

Hospital das Clinicas, HCUFPR Curitiba, Brazil


Follicular fluid thyroid autoantibodies, thyrotropin, free thyroxine levels and assisted reproductive technology outcome.

PloS one
Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Mean Platelet Volume-to-Platelet Count Ratio as Biomarkers in Critically Ill and Injured Patients: Which Ratio to Choose to Predict Outcome and Nature of Bacteremia?

Mediators of inflammation

Choose language »